Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (1724)	5/20/2001 2:10:44 PM
From: Jibacoa	Read Replies (1) \| Respond to of 2344

And BIOMIRA is listed among the 32 companies listed in the table on that article.<g> And of course they forgot to mention that one of BIOM's products is "on late trials". (I have to check DNDN's Provenge. I think Phase III started in January 2000, but I don't remember the target date for conclusion ). Leading the War Against Cancer "At last count some 170 companies were working on 400 potential cancer drugs. Most of these drugs and many of these companies won't make it.But those that do will help turn cancer from a death sentence into a chronic manageable disease". "Cancer is one of the largest untapped disease markets in the world," says analyst C.J. Sylvester of UBS Warburg. "There are tremendous growth opportunities." Below are 32 companies, large and small, engaged in the battle. Large Pharmaceutical Houses: Astrazeneca AZN $48.70 Hormonal drugs for breast, prostate cancers; lung tumor drug in trials. Aventis Ads AVE 77.51 Vaccine, gene therapy and anti-angiogenic compounds. Bristol-Myers Squibb BMY 56.90 Biggest oncology player; pioneering the science of genomics. Novartis NVS 41.99 Leukemia drug, Gleevec, has electrified the industry. Pharmacia PHA 48.38 Top drug for breast, colorectal cancers; anti-angiogenics in early trials. Targeted Drug Therapy: Arena Pharm ARNA 27.20 Targeting cancer receptors. Keryx Biopharm KERX 7.66 Using genomics to generate drugs targeting cell communication. Osi Pharmaceuticals OSIP 40.84 R&D concentrated on small molecule cancer drugs. Vertex Pharm VRTX 32.92 Small molecule drugs for cancer and other diseasesAntibodies. Abgenix ABGX 36.23 Developing drugs for cancer, transplant and auto-immune disorders. Genentech DNA 48.50 65.3 Herceptin, the first monoclonal antibody approved for breast cancer. Idec Pharm IDPH 53.18 A leader in targeted cancer immunotherapies. Imclone Systems IMCL 44.45 Cancer antibodies, cancer vaccines and anti-angiogenesis agents. Immunogen IMGN 15.34 Chemotherapy delivery systems. Immunomedics IMMU 13.11 Monoclonal antibodies to deliver chemotherapy to tumors. Medarex MEDX 23.35 Using mouse antibodies to attack human cancers. MedImmune MEDI 38.44 Anti-cancer antibodies, vaccines and small-molecule drugs. NeoRx NERX 5.46 Radiotherapy to target agents made to bind to cancer. Protein Design Lab PDLI 63.85 717.0 2765 Humanized mouse antibodies that fight tumors. Vaccines: Antigenics AGEN 17.88 Immunotherapeutics based on a 'heat shock' proteins. Avi Biopharma AVII 7.03 Therapeutic cancer vaccines, gene-targeted drugs, drug delivery. Biomira BIOM 7.48 Immunotherapies that mimic the natural cancer antigens. Corixa CRXA 14.80 Cancer-specific antigens and delivery of antigen vaccines. Dendreon DNDN 9.90 Therapeutic vaccine for prostate cancer in late trials Progenics Pharm PGNX 15.21 Vaccines, antibodies to induce an anti-cancer immune response Anti-Angiogenesis Eterna Labs AELA 5.72 Drugs in trials that target lung, prostate and breast cancers Celgene CELG 19.47 Anti-angiogenesis and the tumor-necrosis drugs Entremed ENMD 13.52 A leader in anti-angiogenisis; Endostatin in Phase 1 trials